caa a22 4500 605463565 CHVBK 20210128100254.0 cr unu---uuuuu 210128e20150301xx s 000 0 eng 10.1007/s00774-014-0581-y doi (NATIONALLICENCE)springer-10.1007/s00774-014-0581-y Hegazy Sahar Faculty of Pharmacy, Tanta University, Tanta, Egypt aut Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women [Elektronische Daten] [Sahar Hegazy] Osteoporosis is the most important metabolic bone disease in patients with diabetes mellitus. Several studies have documented that metformin is osteogenic in vitro. In contrast, others showed no effect of metformin on the osteogenic differentiation of bone marrow-derived mesenchymal stem cells. Incretin hormones have received much attention because of their beneficial effects beyond glycemia, including on bone health. The study evaluated the anti-osteoporotic effect of metformin and sitagliptin in postmenopausal diabetic women. Forty postmenopausal diabetic women were randomly divided into two equal groups. Group 1 received metformin (Glucophage® 500mg) 1 tablet twice daily, and group 2 received sitagliptin (Januvia® 100mg) 1tablet/day, for 12weeks. Fasting blood and urine samples were collected for measurement of serum total alkaline phosphatase (ALP), osteocalcin, and urinary deoxypyridinoline (DPD). Laboratory tests were measured at baseline, after 4 and 8weeks, and at the end of the study. Bone mineral density of the anterior posterior lumbar spine was measured by dual energy X-ray absorptiometry at baseline and after 12weeks of the intervention. In the metformin-treated group, the mean values for all markers of bone turnover at 12weeks of treatment were not significantly different from baseline. In group 2, the mean serum total ALP was significantly decreased, serum osteocalcin levels were non-significantly decreased gradually by 10% at 12weeks, while urinary DPD decreased significantly and was then maintained at 28% decrease at 12weeks. In conclusion, metformin is neither osteogenic nor has anti-osteoporotic effect, while sitagliptin could positively regulate bone metabolism. The Japanese Society for Bone and Mineral Research and Springer Japan, 2014 Osteoporosis nationallicence Diabetes nationallicence Postmenopause nationallicence Metformin nationallicence Sitagliptin nationallicence Journal of Bone and Mineral Metabolism Springer Japan 33/2(2015-03-01), 207-212 0914-8779 33:2<207 2015 33 774 https://doi.org/10.1007/s00774-014-0581-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00774-014-0581-y text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Hegazy Sahar Faculty of Pharmacy, Tanta University, Tanta, Egypt aut NATIONALLICENCE 773 0- Journal of Bone and Mineral Metabolism Springer Japan 33/2(2015-03-01), 207-212 0914-8779 33:2<207 2015 33 774